AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.07
0.05 (4.90%)
▲
5d:
+18.97%
30d:
+19.54%
90d:
-24.65%
BUY
HIGH Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.07, which is considered slightly high relative to its 30-day fair value range of $0.93 to $1.09. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.6) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a strong downtrend. The price is approaching resistance at $1.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+292.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AKBA is in a strong downtrend. The price is approaching resistance at $1.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: AKBA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.20 (+292.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.93 -
$1.09
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 292.5% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.93 -
$1.09
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.82
Resistance Level
$1.08
Current Trend
Strong Downtrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.63
Wall Street Target
$4.20
(+292.5%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-5.6 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: June 19, 2026 6:57 PM ET
Data refreshes hourly during market hours. Next update: 7:57 PM
Data refreshes hourly during market hours. Next update: 7:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 58 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
